Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects of glutaminase inhibitor CB-839 in combination
with azacitidine in treating patients with myelodysplastic syndrome that has spread to other
places in the body. Glutaminase inhibitor CB-839 and azacitidine may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Calithera Biosciences, Inc National Cancer Institute (NCI)